1-3 of 3
S. Corm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcome of Relapsed AML Patients Aged between 50 and 70: The ALFA Group Experience (ALFA 9801 Study).

F. Merabet, N. Boissel, O. Reman, Jean-Henri Bourhis, B. Quesnel, S. Rigaudeau, C. Cordonnier, D. Bordessoule, H. Tilly, S. Corm, M. Michallet, J.M. Miclea, X. Thomas, S. Chevret, P. Fenaux, S. Castaigne
Journal: Blood
Blood (2007) 110 (11): 1857.
https://doi.org/10.1182/blood.V110.11.1857.1857
Published: 2007
Journal Articles

Variant Philadelphia-Positive Chronic Myeloid Leukemia, der(9) Deletions and Response to Imatinib Mesylate: A Retrospective Multicentric Analysis from the French Fi-LMC Group.

S. Corm, MD, Franck Nicolini, S. Richebourg, F. Huguet, D. Rea, I. Tigaud, N. Dastugue, S. Raynaud, L. Legros, J. van den Akker, F.X. Mahon, F. Maloisel, C. Roche-Lestienne, A. Guerci, C. Preudhomme, V. Eclache
Journal: Blood
Blood (2006) 108 (11): 2113.
https://doi.org/10.1182/blood.V108.11.2113.2113
Published: 2006
Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

M. Talpaz, P. Rousselot, D.W. Kim, F. Guilhot, S. Corm, E. Bleickardt, R. Zink, G. Rosti, S. Coutre, C. Sawyers
Journal: Blood
Blood (2005) 106 (11): 40.
https://doi.org/10.1182/blood.V106.11.40.40
Published: 2005